West Pharmaceutical Services, Inc.

NYSE:WST Rapport sur les actions

Capitalisation boursière : US$21.6b

West Pharmaceutical Services Croissance future

Future contrôle des critères 1/6

West Pharmaceutical Services devrait augmenter ses bénéfices et son chiffre d'affaires de 10.2% et de 6.1% par an respectivement. Le BPA devrait croître de de 10.2% par an. Le rendement des capitaux propres devrait être 18.5% dans 3 ans.

Informations clés

10.2%

Taux de croissance des bénéfices

10.20%

Taux de croissance du BPA

Life Sciences croissance des bénéfices17.6%
Taux de croissance des recettes6.1%
Rendement futur des capitaux propres18.54%
Couverture par les analystes

Good

Dernière mise à jour20 May 2026

Mises à jour récentes de la croissance future

Recent updates

Seeking Alpha • Apr 30

West Pharmaceutical: Multiple Growth Drivers Are A Tailwind

Summary West Pharmaceutical Services maintains dominant market share in injectable drug delivery, underpinned by a wide moat and robust regulatory positioning. WST reported strong Q1 2026 results, with revenue up 21% and adjusted EPS up 46.9%, prompting a guidance raise and share price rebound. Key growth drivers include biologics market expansion, GLP-1 drug demand, and Annex 1 regulatory upgrades, supporting recurring revenue and margin strength. I rate WST a long-term 'hold' due to exemplary dividend safety and a fortress balance sheet, but the current valuation is only slightly below fair value. Read the full article on Seeking Alpha
Mise à jour du récit • Apr 27

WST: Higher Margin Mix And Contract Services Expansion Will Support Earnings Power

Analysts have lifted the implied fair value estimate for West Pharmaceutical Services by about $11 to roughly $350, as a series of recent price target changes reflect updated assumptions around growth, margins and P/E multiples. Analyst Commentary Recent Street research on West Pharmaceutical Services shows a mix of upbeat and cautious messages as analysts recalibrate their models and price targets around updated assumptions for growth, margins and P/E multiples.
Mise à jour du récit • Feb 07

WST: Margin Resilience And Drug Delivery Portfolio Shift Will Support Earnings Power

Analysts have trimmed their price target on West Pharmaceutical Services by about US$7. This reflects updated assumptions around slightly softer revenue growth, a modestly higher discount rate, a small adjustment to future P/E expectations, and a marginally stronger profit margin outlook.
Mise à jour du récit • Jan 24

WST: 2026 Drug Delivery Focus And New Syringe Platform Will Support Earnings Power

Analysts have kept their fair value estimate for West Pharmaceutical Services steady at about $345.71 per share, with only slight tweaks to assumptions like the discount rate, long term revenue growth, profit margin, and future P/E, which together feed into their updated price target narrative. What's in the News West Pharmaceutical Services agreed to sell all manufacturing and supply rights for its SmartDose 3.5 mL On Body Delivery System, along with associated facilities, to AbbVie for total consideration of US$112.5 million at close, subject to working capital and other adjustments (Key Developments).
Mise à jour du récit • Jan 07

WST: Normalizing Markets And 2026 Visibility Will Support Earnings Power

Narrative update The updated analyst price target for West Pharmaceutical Services reflects a largely steady fair value near US$346. Analysts point to recent target hikes, higher EPS estimates and a constructive view on growth drivers into 2026 as key supports for the current valuation framework.
Mise à jour du récit • Dec 19

WST: Normalizing End Markets Will Support Stronger Earnings Base Into 2026

Analysts have modestly raised their price target on West Pharmaceutical Services to approximately $370, up from about $310. This reflects increased earnings estimates, a stronger setup into 2026, and improving, more stable end markets.
Mise à jour du récit • Dec 05

WST: Normalizing End Markets Will Support Strong Earnings Base Into 2026

Analysts have nudged their price target for West Pharmaceutical Services slightly higher to approximately $370, reflecting increased confidence in the company’s earnings power and growth drivers as market conditions normalize and set up favorably into 2026. Analyst Commentary Analyst views on West Pharmaceutical Services remain broadly constructive, with recent target hikes reflecting growing conviction that the company can sustain its earnings recovery as end markets normalize into 2026.
Mise à jour du récit • Nov 21

WST: Strong 2025 Outlook and Management Confidence Will Sustain Positive Momentum

West Pharmaceutical Services has seen its average analyst price target raised, with significant increases attributed to strong quarterly results, growing end market confidence, and a positive management outlook for 2026, according to analysts. Analyst Commentary Analysts have responded to West Pharmaceutical Services' recent performance and outlook with a range of observations tying directly to the company's valuation, execution, and growth prospects.
Mise à jour du récit • Nov 07

WST: Sustained Earnings Momentum Will Drive Confidence Into 2026

West Pharmaceutical Services has seen its average analyst price target rise from approximately $321 to $351. Analysts cite continued growth drivers and improved market conditions following a strong quarterly performance.
Mise à jour du récit • Oct 23

Analysts Raise Target for West Pharmaceutical Services Amid Strong Outlook and Upgraded Guidance

Analysts have increased their price target for West Pharmaceutical Services by $5 to $321. They cited the company's encouraging earnings call, management's confidence in future estimates, and stable end markets with improving investment sentiment.
Article d’analyse • Jul 25

West Pharmaceutical Services, Inc.'s (NYSE:WST) Shares Climb 25% But Its Business Is Yet to Catch Up

West Pharmaceutical Services, Inc. ( NYSE:WST ) shareholders have had their patience rewarded with a 25% share price...
Article d’analyse • Jul 13

Here's Why West Pharmaceutical Services (NYSE:WST) Can Manage Its Debt Responsibly

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Seeking Alpha • Mar 11

West Pharmaceutical: Remains A Strong Long-Term Prospect

Summary West Pharmaceutical Services has faced a challenging year, underperforming against the index, with declining volumes, margins, and returns, but remains a strong long-term investment. The company's high-value products segment, driven by GLP-1 medications and biologics, is expected to boost margins and returns significantly. Despite poor timing in share buybacks and management concerns, West's valuation suggests a potential 12.8% annual return, making it a buy. Key risks include management's strategic decisions and valuation, but the worst seems behind, with attractive prices for long-term growth. Read the full article on Seeking Alpha
Seeking Alpha • Feb 17

West Pharmaceuticals Takes A Plunge, But May Still Offer Opportunities

Summary The price of West Pharmaceutical Services plunged over 38% after it released its Q4 and FY 2024 earnings results on February 13. Shareholders, mostly institutional investors apparently, did not like the bottom-line results nor the uninspiring guidance for 2025. Still, West should not be overlooked, and there may be opportunities if the share price continues to rebound after a market overreaction. Read the full article on Seeking Alpha
Seeking Alpha • Jan 08

West Pharmaceuticals: Cannot Wrap My Head Around Valuations (Rating Downgrade)

Summary West Pharmaceutical Services stock is down 16% on deteriorating fundamentals. WST's business is contracting, with lower sales growth, compressed margins, and declining ROIC, making current valuations unjustifiable. Industry advantages exist, but high multiples and low incremental returns suggest limited compounding ability. I revise WST to hold with a $300-$330/share valuation, emphasizing the need for it to produce 4%+ sales growth and improved ROIC FY'26 to justify current prices. Read the full article on Seeking Alpha
Seeking Alpha • Oct 11

West Pharma's Destocking Dilemma: Why Staying On The Sidelines Makes Sense

Summary West Pharmaceutical Services' stock has been sluggish, trading near its 52-week low, with analysts downgrading estimates and technical indicators pointing to further downside. The company has a strong market position in injectable drug delivery systems, but post-COVID demand normalization and destocking have impacted recent performance. Despite robust seasonal trends, the stock is vulnerable to tax-loss selling, with Morgan Stanley naming it among the most at-risk stocks. Given these factors, a cautious hold on West Pharma is recommended, awaiting potential recovery in Q4 and beyond. Read the full article on Seeking Alpha

Prévisions de croissance des bénéfices et des revenus

NYSE:WST - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20283,7867715748638
12/31/20273,53869051378714
12/31/20263,33160744672614
3/31/20263,221543458715N/A
12/31/20253,074494469755N/A
9/30/20253,018492379694N/A
6/30/20252,960488344677N/A
3/31/20252,896467307665N/A
12/31/20242,893493276653N/A
9/30/20242,876500322702N/A
6/30/20242,877525357752N/A
3/31/20242,929569386757N/A
12/31/20232,950593415777N/A
9/30/20232,927559420768N/A
6/30/20232,866519397707N/A
3/31/20232,884552410711N/A
12/31/20222,887586439724N/A
9/30/20222,909631388654N/A
6/30/20222,929686402675N/A
3/31/20222,881684382647N/A
12/31/20212,832662331584N/A
9/30/20212,681613341572N/A
6/30/20212,523519287500N/A
3/31/20212,326423307504N/A
12/31/20202,147346298473N/A
9/30/20202,037312272430N/A
6/30/20201,945286277420N/A
3/31/20201,888261247377N/A
12/31/20191,840242N/A367N/A
9/30/20191,792230N/A334N/A
6/30/20191,767229N/A314N/A
3/31/20191,745219N/A291N/A
12/31/20181,717207N/A289N/A
9/30/20181,711155N/A297N/A
6/30/20181,677151N/A284N/A
3/31/20181,627133N/A288N/A
12/31/20171,599151N/A263N/A
9/30/20171,566190N/A254N/A
6/30/20171,544176N/A246N/A
3/31/20171,535182N/A237N/A
12/31/20161,509144N/A219N/A
9/30/20161,487138N/A216N/A
6/30/20161,454102N/A216N/A
3/31/20161,42685N/A217N/A
12/31/20151,40096N/A212N/A
9/30/20151,39094N/A190N/A
6/30/20151,401123N/A186N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de WST ( 10.2% par an) est supérieure au taux d'épargne ( 3.5% ).

Bénéfices vs marché: Les bénéfices de WST ( 10.2% par an) devraient croître plus lentement que le marché US ( 16.7% par an).

Croissance élevée des bénéfices: Les bénéfices de WST devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de WST ( 6.1% par an) devrait croître plus lentement que le marché de US ( 11.7% par an).

Croissance élevée des revenus: Le chiffre d'affaires de WST ( 6.1% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de WST devrait être faible dans 3 ans ( 18.5 %).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/21 08:02
Cours de l'action en fin de journée2026/05/21 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

West Pharmaceutical Services, Inc. est couverte par 25 analystes. 14 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Luke SergottBarclays
Lawrence MarshBarclays
Michael RyskinBofA Global Research